scholarly journals Neuroendocrine Carcinoma of the Colon with Repeated Local Recurrences: A Report a Case

2013 ◽  
Vol 38 (4) ◽  
pp. 869-874
Author(s):  
Tomohiro Kunishige ◽  
Tomohide Mukogawa ◽  
Hirohumi Ishikawa ◽  
Saiho Ko ◽  
Akihiko Watanabe ◽  
...  
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Carcinoma Of The Colon ◽  
Local Recurrences

scholarly journals Neuroendocrine carcinoma of the colon presenting as acute meningitis

BMC Neurology ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Julie R. Bloom ◽  
Arlen Brickman ◽  
Fan J. Yang ◽  
Ji-Weon Park ◽  
Jonathan Cheponis
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Carcinoma Of The Colon ◽  
Acute Meningitis

High-grade Metastatic Neuroendocrine Carcinoma of the Colon

2013 ◽  
Vol 108 ◽  
pp. S395
Author(s):  
Raja Taunk ◽  
David Robbins ◽  
Parswa Ansari ◽  
Mark Westcott
Keyword(s):  
Neuroendocrine Carcinoma ◽  
High Grade ◽  
Carcinoma Of The Colon

BRAF mutations in patients with large cell neuroendocrine carcinoma of the colon (LCNECC).

2016 ◽  
Vol 34 (4_suppl) ◽  
pp. 567-567
Author(s):  
Karuna Ganesh ◽  
Nitya Prabhakar Raj ◽  
Rona D. Yaeger ◽  
Michael F. Berger ◽  
Jinru Shia ◽  
...  
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Impact Analysis ◽  
Cell Cancer ◽  
Braf Inhibitor ◽  
Large Cell ◽  
Small Cell ◽  
Braf V600e ◽  
Cell Of Origin ◽  
Braf Mutations ◽  
Carcinoma Of The Colon

567 Background: LCNECC is a rare, poorly differentiated neoplasm with a median survival of 13 months. The cell of origin, genetic mediators and optimal clinical management of LCNECC are unknown. Current guidelines recommend treatment with platinum and etoposide, but nearly all patients rapidly fail therapy. Identification of actionable genomic alterations in LCNECC may lead to improved outcomes. Methods: We identified 123 patients (1.1%) with LCNECC or non-small cell high-grade neuroendocrine carcinoma of the colon or rectum, out of 11134 colorectal cancers treated at MSKCC from 1991-2015. Genomic testing had been performed on 8 tumors: 5 using mass spectrometry based genotyping of 8 genes and 3 using hybridization exon capture of 341 cancer-associated genes (MSK IMPACT). Results: BRAF V600E mutations were identified in 5/8 (62.5%) LCNECCs. One patient each had KRAS Q61H and G12V mutations. Only 2/8 patients had TP53 mutations. All 5 patients with BRAF V600E mutations had non-regional lymphadenopathy, consistent with the metastatic pattern seen in BRAF-mutant colorectal adenocarcinoma (CRC). One patient, a 52-year old female with metastatic LCNECC, was first treated with cisplatin/irinotecan but progressed after 2 cycles. She was treated with FOLFOX, with dramatic clinical and radiological response lasting 7 months. BRAFV600E mutation was identified, and she was treated with dabrafenib+trametinib with radiologically stable disease at 2 months. In sum, 4/6 evaluable patients treated with first line FOLFOX, and 3/3 patients receiving second line FOLFOX after disease progression on cisplatin-based therapy achieved radiological responses. Conclusions: BRAF and KRAS hotspot mutations are near universal features of LCNECC, suggesting that LCNECC is an ERK driven tumor. BRAF inhibitor therapy was associated with clinical benefit in one LCNECC patient. Mutations in TP53, RB1 and PTEN, frequent in small cell cancer, are uncommon in LCNECC. Moreover, several patients responded to FOLFOX, a standard of care for CRC. Together, the mutation patterns and therapy responses suggest some similarities between LCNECC and CRC. MSK IMPACT analysis of further LCNECCs is underway and will be reported at the meeting.

1629 A Rare Case of Large Cell Neuroendocrine Carcinoma of the Colon

2019 ◽  
Vol 114 (1) ◽  
pp. S911-S911
Author(s):  
Yiu-Ting T. Chiu ◽  
Sherif Michael ◽  
Kelli Morgan ◽  
Navid Mokhtari ◽  
Mindie Kavanaugh ◽  
...  
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Rare Case ◽  
Large Cell ◽  
Large Cell Neuroendocrine Carcinoma ◽  
Carcinoma Of The Colon

High-grade neuroendocrine carcinoma of the colon, long-term survival in advanced disease

2010 ◽  
Vol 28 (S1) ◽  
pp. 169-174 ◽  
Author(s):  
Derek G. Power ◽  
Timothy R. Asmis ◽  
Laura H. Tang ◽  
Karen Brown ◽  
Nancy E. Kemeny
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Advanced Disease ◽  
High Grade ◽  
Term Survival ◽  
Long Term Survival ◽  
Carcinoma Of The Colon

scholarly journals Mixed Neuroendocrine Carcinoma and Squamous Cell Carcinoma of the Colon: Case Report and Literature Review

2018 ◽  
Vol 12 (2) ◽  
pp. 240-246 ◽  
Author(s):  
Shinya Munakata ◽  
Yuta Murai ◽  
Akihiro Koizumi ◽  
Hisaki Kato ◽  
Riku Yamamoto ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Neuroendocrine Carcinoma ◽  
Squamous Cell ◽  
Lung Metastases ◽  
Carcinoma Of The Colon ◽  
Additional Chemotherapy ◽  
Old Japanese ◽  
Descending Colon Cancer

Neuroendocrine carcinoma (NEC) of the colon is very rare, and squamous cell carcinoma (SCC) of colon cancer is rare. We recently treated a patient with both NEC and SCC that initially presented as multiple unresectable liver and lung metastases. A 68-year-old Japanese man was referred to our hospital because of diarrhea with descending colon cancer obstruction. He underwent a left colectomy. Based on immunohistochemistry results, we diagnosed mixed NEC and SCC, the primary lesion location of which was probably the lung in the final pathologic examination. He began systemic palliative chemotherapy with CDDP and CPT-11. After 3 months of treatment, shown the progressive disease, we started CDDP and VP-16. The patient was not eligible for additional chemotherapy after 2 months.

scholarly journals Synchronous adenocarcinoma and neuroendocrine carcinoma of the colon: a case report

2016 ◽  
Vol 2016 (3) ◽  
Author(s):  
Sonmoon Mohapatra ◽  
Mohammad Ibrarullah ◽  
Ashutosh Mohapatra ◽  
Manas Ranjan Baisakh
Keyword(s):  
Case Report ◽  
Neuroendocrine Carcinoma ◽  
Carcinoma Of The Colon
Sign in / Sign up

Export Citation Format

Share Document